Hyperbaric Oxygen therapy helps the body fight solid tumors
The emergence of cancer immunotherapy has already shown some remarkable results for the treatment of solid tumors. As good as this is, patients, seem to lack the ability to respond to immune checkpoint inhibitors, thus demonstrating a primary resistance to immunotherapy.
By reducing tumor hypoxia (low oxygen) within solid tumors. hyperbaric oxygen therapy (HBOT) can help reinvigorate anti-cancer immunity.
In this study, HBOT was able to stimulate a suppressed immune system and help PD-1 Ab trigger robust cytotoxic T lymphocytes and long-lasting immunological memory to inhibit tumor relapses.
Emerging research suggests that T cell-directed checkpoint antibodies such as anti-programmed cell death protein-1 (PD-1) or programmed death-ligand-1 (PD-L1) can impact innate immunity by both direct and indirect pathways, which may ultimately shape clinical efficacy. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to “trick” the immune system, and avoid being attacked by foreign, harmful substances.
Hyperbaric Oxygen Boosts PD-1 Antibody Delivery — “The results illustrate that HBO bolsters antitumor efficacy of PD-1 Ab, and the HBO-PD-1 Ab combination is a promising stroma-rich solid tumors’ treatment in the clinic” <view study>
The emergence of cancer immunotherapy has already shown some remarkable results for the treatment of solid tumors. As good as this is, patients, seem to lack the ability to respond to immune checkpoint inhibitors, thus demonstrating a primary resistance to immunotherapy.
By reducing tumor hypoxia (low oxygen) within solid tumors. hyperbaric oxygen therapy (HBOT) can help reinvigorate anti-cancer immunity.
In this study, HBOT was able to stimulate a suppressed immune system and help PD-1 Ab trigger robust cytotoxic T lymphocytes and long-lasting immunological memory to inhibit tumor relapses.
Emerging research suggests that T cell-directed checkpoint antibodies such as anti-programmed cell death protein-1 (PD-1) or programmed death-ligand-1 (PD-L1) can impact innate immunity by both direct and indirect pathways, which may ultimately shape clinical efficacy. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to “trick” the immune system, and avoid being attacked by foreign, harmful substances.
Hyperbaric Oxygen Boosts PD-1 Antibody Delivery — “The results illustrate that HBO bolsters antitumor efficacy of PD-1 Ab, and the HBO-PD-1 Ab combination is a promising stroma-rich solid tumors’ treatment in the clinic” <view study>
Turn back the aging clock — Hyperbaric oxygen therapy REVERSES telomere length, a critical determinant in the aging process
Telomere length serves as a biological clock to determine our lifespan. Every year, our telomeres (the ends of our DNA) get shorter until they finally shorten to a length that leads to our mortality.
Over the past few decades, researchers and drug companies have focused (and invested substantial capital) on this key biological determinant (telomere length) in the hopes of being able to stop and reverse the aging process.</p>
Since many age-related diseases (like cancer, cardiovascular diseases, diabetes and Alzheimer’s) are also linked to shortened telmeres, it is easy to see why so many drug and nutritional companies have been working hard on finding a cure to stop and reverse the shortening of telomeres.
Hyperbaric oxygen therapy has already been demonstrated in clinical studies to help the aging population by reducing the signs of aging and age-related diseases. In 2006, a landmark study showed an 800% increase in stem cell mobilization from a course of hyperbaric oxygen therapy. This gave us a much better understanding of the physiological benefits of this procedure in relation to the aging process.
Today we have even more information as a second landmark study has been published on the effects of hyperbaric therapy in regards to telomere length. In this study, a 3 month course of hyperbaric therapy produced a profound increase in telomere length by 20% – 38%. (This is higher than any other intervention currently available). The hyperbaric protocol used to produce these benefits included 60 hyperbaric sessions (each at 90 minute sessions at 2.0 ATA with 3 air breaks). This exciting new study will surely lead to many more telomere-based studies in the field of hyperbaric oxygen therapy and further help to advance our knowledge of this therapy <View Full Study> in the JOURNAL OF AGING.
Due to the significance of this study, it has quickly been picked up by many news associations like the following:
Telomere length serves as a biological clock to determine our lifespan. Every year, our telomeres (the ends of our DNA) get shorter until they finally shorten to a length that leads to our mortality.
Over the past few decades, researchers and drug companies have focused (and invested substantial capital) on this key biological determinant (telomere length) in the hopes of being able to stop and reverse the aging process.
Since many age-related diseases (like cancer, cardiovascular diseases, diabetes and Alzheimer’s) are also linked to shortened telmeres, it is easy to see why so many drug and nutritional companies have been working hard on finding a cure to stop and reverse the shortening of telomeres.
Hyperbaric oxygen therapy has already been demonstrated in clinical studies to help the aging population by reducing the signs of aging and age-related diseases. In 2006, a landmark study showed an 800% increase in stem cell mobilization from a course of hyperbaric oxygen therapy. This gave us a much better understanding of the physiological benefits of this procedure in relation to the aging process.
Today we have even more information as a second landmark study has been published on the effects of hyperbaric therapy in regards to telomere length. In this study, a 3 month course of hyperbaric therapy produced a profound increase in telomere length by 20% – 38%. (This is higher than any other intervention currently available). The hyperbaric protocol used to produce these benefits included 60 hyperbaric sessions (each at 90 minute sessions at 2.0 ATA with 3 air breaks).
This exciting new study will surely lead to many more telomere-based studies in the field of hyperbaric oxygen therapy and further help to advance our knowledge of this therapy. View Full Study in the JOURNAL OF AGING
Due to the significance of this study, it has quickly been picked up by many news associations like the following:
The effect of hyperbaric oxygen treatment on late radiation tissue injury after breast cancer
“In this case series, 67 patients who underwent HBOT for late radiation tissue injury after breast cancer reported significant improvement in pain, fibrosis, edema, and shoulder movement. The improvement
“In this case series, 67 patients who underwent HBOT for late radiation tissue injury after breast cancer reported significant improvement in pain, fibrosis, edema, and shoulder movement. The improvement persisted up to 12 months after HBOT” view study.
Hyperbaric Oxygen Therapy
Aging
Anxiety
Arthritis
Athletes
Autism
Bone Healing
Brain Health
Cancer
Cellular Energy
Cerebral Palsy
Chronic Infection
Concussion
COVID-19
Degenerative Disc Disease
Depression
Diabetes
Drug & Alcohol
Eczema
Erectile Dysfunction
Fatigue (chronic)
Fetal Alcohol Syndrome
Fibromyalgia
Fragile X syndrome
GI Tract
Hearing
Heart
High Blood Pressure
HIV infection
Hyperbaric Ambient Air Pressure
Inflammation
Liver Disease
Macular Degeneration
Migraine Headaches
Mild Hyperbarics (m-HBOT)
Mold
Multiple Sclerosis
Obesity
Organ Transplant
Osteoporosis
Pain (chronic)
Parkinson's Disease
Protection
PTSD
Pulmonary Fibrosis
Spinal Cord Injury
Stem Cells
Stroke
Surgery (plastic/reconstructive)
Teeth and Gums
Tissue & Nerve Regeneration
Traumatic Brain Injury (TBI)
Vision
Wound Healing